Last reviewed · How we verify
NCT03936348: EPOC_2_0
Effects of an Exercise Rehabilitation Programme With a Nasal Inspiratory Restriction Device in COPD Patients
NA trial testing Exercise training program with and without FB in Pulmonary Disease, Chronic Obstructive in 16 participants. Completed in 18 December 2017.
25 July 2017
Quick facts
| Lead sponsor | University of Cadiz |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 15 January 2016 |
| Primary completion | 25 July 2017 |
| Estimated completion | 18 December 2017 |
Drugs / interventions tested
- Exercise training program with and without FB
Conditions studied
- Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →
- Breathing Exercises — all drugs for Breathing Exercises →
- Exercise Tolerance — all drugs for Exercise Tolerance →
Sponsor
University of Cadiz
Who can join
Adults 35 to 65, male only, with Pulmonary Disease, Chronic Obstructive or Breathing Exercises. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the effects of a nasal restriction device for inspiratory muscle training (FeelBreathe) after 8 weeks of exercise intervention on exercise capacity, quality of life, dyspnea and inspitarotory muscle strength in patients with stable COPD. Participants were divided in three groups: 1) exercise intervention using the Feelbreathe® device (FB group), 2) exercise intervention with oronasal breathing without FB (ONB group) and 3) no participation in the exercise intervention as control group (CG).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of a Rehabilitation Programme with a Nasal Inspiratory Restriction Device on Exercise Capacity and Quality of Life in COPD.
Arnedillo A, Gonzalez-Montesinos JL, Fernandez-Santos JR, Vaz-Pardal C, et al · · 2020 · cited 9× · PMID 32456097 · DOI 10.3390/ijerph17103669
Verify or expand the search:
- PubMed search for NCT03936348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Disease, Chronic Obstructive
Currently open trials in the same condition.
- NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
- NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting
Other University of Cadiz trials
Trials by the same sponsor.
- NCT07584343 — EMG of Gait Under Dual-Task in Parkinson Desease · completed
- NCT07267468 — Effectiveness of an mHealth Intervention, Based on Rehabilitation and a Personalised Nutrition Plan, in the Recovery and · NA · recruiting
- NCT07251322 — Relationship Between Frailty and Gut Microbiota in Older Adults: An Educational Program for Healthy Aging · completed
- NCT06729138 — Resisted Training in Runners · NA · completed
- NCT06871072 — Telerehabilitation for Multiple Sclerosis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03936348 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cadiz
- Last refreshed: 31 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03936348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing